Why the study?
Does sardine peptide or captopril improve glucose tolerance in stroke-prone spontaneously hypertensive rats?
Does sardine peptide or captopril improve glucose tolerance in stroke-prone spontaneously hypertensive rats?
Sardine peptide with ACE inhibitory activity improves glucose tolerance in stroke-prone spontaneously hypertensive rats, demonstrating effects similar to captopril.
May improve post-load glucose tolerance in hypertensive rat models; leaves open translation to human cardiometabolic care.
An enzymatic hydrolysate of sardine protein (sardine peptide, SP) derived from sardine muscle possesses angiotensin I-converting enzyme (ACE) inhibitory activity. In the present study, we investigated the effect of SP on the blood glucose levels in stroke-prone spontaneously hypertensive rats (SHRSPs). Ten-week-old SHRSPs were assigned to three groups. The control group was given tap water for 4 weeks, while the experimental groups were given water containing SP (1 g/kg/d) or an ACE inhibitor, captopril (8 mg/kg/d). Treatment with SP and captopril decreased ACE activity in the kidney, aorta, and mesentery. There were no differences in fasting blood glucose levels among the three groups, whereas SP and captopril administration significantly suppressed the increase in blood glucose after glucose loading in the control SHRSPs. No difference was observed in plasma insulin levels among the three groups. Thus treatment with captopril and ACE-inhibitory sardine peptides ameliorated the glucose tolerance of this rat strain.
No takes yet. Share an insight, caveat, or question.
Otani et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: